Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00604162
Other study ID # MA-53
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date October 2006
Est. completion date October 2007

Study information

Verified date August 2010
Source Medtronic - MITG
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To see if PillCam COLON will demonstrate diagnostic yield >80% in detecting significant colonic pathologies when compared to colonoscopy in the target population.


Description:

The development and introduction of a specially designed, customized colon capsule combined with a dedicated capsule colonoscopy procedure protocol will allow for more efficient evaluation of the colonic mucosa. This is expected to improve the capability of the Given® Diagnostic System to detect colonic pathologies and to serve as a diagnostic and screening tool for colonic disease.

This study is designed to compare capsule colonoscopy and colonoscopy procedures in detecting colon abnormalities. Note that the physician performing the capsule endoscopy and reading the capsule videos and the physician performing the colonoscopy were unaware of each other's findings until completion of the examinations and reports (assessor-blind).


Recruitment information / eligibility

Status Completed
Enrollment 332
Est. completion date October 2007
Est. primary completion date October 2007
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Subject was referred for colonoscopy for one of the following reasons:

- Subjects over = 50 years of age with one or more of the following clinical symptoms: rectal bleeding, hematochezia, melena, positive Fecal Occoult Blood Test (FOBT), recent change of bowel habits, or diarrhea/constipation of recent onset.

- Any subject = 18 years of age with:

- Positive findings in the colon on a GastroIntestinal (GI) radiographic study

- Personal history of colorectal cancer (CRC) or adenomatous colonic polyps and at least 3 years since last colonoscopy

- Suspected or known ulcerative colitis

Exclusion Criteria:

- Subject has dysphagia

- Subject has congestive heart failure

- Subject has renal insufficiency

- Subject is known or is suspected to suffer from intestinal obstruction.

- Chronic use of laxatives

- Subject has a cardiac pacemakers or other implanted electro medical devices.

- Women who are either pregnant or nursing at the time of screening, who intend to be during the study period, or are of child-bearing potential and do not practice medically acceptable methods of contraception.

- Subject is expected to undergo MRI examination within 7 days after ingestion of the capsule.

- Subject has had prior abdominal surgery of the gastrointestinal tract other than uncomplicated procedures that would be unlikely to lead to bowel obstruction based on the clinical judgment of the investigator.

- Subject has any condition, which precludes compliance with study and/or device instructions.

- Age < 18 years

- Subject suffers from life threatening conditions

- Subject is currently participating in another clinical study

- Subject has known slow gastric emptying time

Study Design


Related Conditions & MeSH terms


Intervention

Device:
PillCam COLON
The PillCam COLON capsule is an ingestible capsule equipped with an endoscope that has two imagers, enabling it to acquire video images from both ends. the device measures 31 by 11 mm and acquires images at a rate of 4 frames per second. Recording and downloading of data are similar those of the data for small-bowel capsule endoscopy.
Procedure:
Standard colonoscopy
Standard colonoscopy was the standard against which capsule endoscopy was compared,and it was performed after capsule endoscopy (after capsule excretion or at least 10 hours after capsule ingestion, whichever came first), on either the same day as ingestion or the next morning.

Locations

Country Name City State
France CHU Lyon Lyon
France CHU Nancy Nancy
Germany Evangelisches Krankenhaus Dusseldorf
Germany AK Altona Hamburg
Italy Ospedale Gemelli Rome
Spain Clinica Universitaria de Navarra Pamplona
United Kingdom St.Marks&Northwick Park hospital Harrow

Sponsors (1)

Lead Sponsor Collaborator
Medtronic - MITG

Countries where clinical trial is conducted

France,  Germany,  Italy,  Spain,  United Kingdom, 

References & Publications (1)

Van Gossum A, Munoz-Navas M, Fernandez-Urien I, Carretero C, Gay G, Delvaux M, Lapalus MG, Ponchon T, Neuhaus H, Philipper M, Costamagna G, Riccioni ME, Spada C, Petruzziello L, Fraser C, Postgate A, Fitzpatrick A, Hagenmuller F, Keuchel M, Schoofs N, Dev — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Successful Capsule Endoscopies or Standard Colonoscopies The number of participants that completed the capsule endoscopy procedure with video images of the entire colon that could be read by a clinician, or subsequently had a full colonoscopy with visualization by a different clinician. The number of successful procedures of each type are reported. 1 day
Primary Number of Participants With Indicated Lesions Detected by Standard Colonoscopy Since the standard colonoscopy is the "gold standard" to which the PillCam is to be compared, the number of participants with the indicated lesions identified by a trained clinician using standard colonoscopy procedures is reported here. Note that some Participants had multiple lesions and so could be included in more than one size category. Advanced adenoma is defined as 1) an adenoma 1 cm or larger or 2) an adenoma with villous features or high-grade dysplasia. All colorectal cancers were 6mm or larger. 1 day
Primary Sensitivity of Capsule Endoscopy for Indicated Lesions Readings of videos from the PillCam COLON were performed by trained physicians who identified lesions (types and sizes). Sensitivity was calculated as the percentage of participants who had positive findings on capsule endoscopy (of a specified category) among those participants who had positive findings on colonoscopy of the same category (reported in Outcome Measure 1). The false negative rate is equal to 1 - sensitivity and indicated the percentage of lesions missed by capsule endoscopy. 1 day
Primary Specificity of Capsule Endoscopy for Indicated Lesions Readings of videos from the PillCam COLON were performed by trained physicians who identified lesions (types and sizes). Specificity was calculated as the percentage of participants who had negative findings on capsule endoscopy (of a specified category) among participants with negative colonoscopy findings of the same category (reported in Outcome Measure 1). This corresponds to 1 - the false positive rate. 1 day
Secondary Percent of Participants With Scoring Index 3 or 4 Overall colon cleanliness was judged for capsule endoscopy and colonoscopy on a four-point grading index scale as follows:
poor cleansing level (Large amount of fecal residue.)
fair cleansing level (Enough feces or dark fluid present to preclude a completely reliable examination.)
good cleansing level (Small amount of feces or dark fluid, but not enough to interfere with examination.)
excellent cleansing level (No more than small bits of adherent feces.)
1 day
Secondary Number, Type and Severity of Adverse Events Within 7 days
Secondary Accuracy Parameters (Sensitivity, Specificity, Negative Predicted Value, Positive Predicted Value) of Colon Capsule Endoscopy, Compared to Standard Colonoscopy within 7 days
Secondary Percentage of Excreted Colon Capsules Within 7 days
Secondary Colon Capsule Endoscopy Transit Time Per Section (Stomach, Small Bowel, Colon) within 7 days
See also
  Status Clinical Trial Phase
Completed NCT02503696 - Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD) N/A
Terminated NCT01119027 - Assessing Effectiveness of Laparoscopic Colorectal Surgical Skills N/A
Completed NCT01063231 - Evaluation of PillCam™ Colon 2 in Visualization of the Colon Phase 3
Completed NCT04074577 - Computer Aided Detection, Tandem Colonoscopy Study N/A
Not yet recruiting NCT04087824 - Deep Learning Algorithm for Recognition of Colonic Segments. N/A
Completed NCT03559543 - Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma Phase 2
Terminated NCT02503631 - Stool Sample Collection Protocol for Development of Screening Test for Colorectal Cancer and Other Digestive Tract Cancers
Completed NCT01600209 - Exact CRC Screening Test: Stool Sample Collection Study to Support Assay Validation Testing N/A
Completed NCT01260168 - Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies N/A
Recruiting NCT04598880 - Comparison of 1 Liter PEG With Ascorbate and Sodium Picosulfate / Magnesium Citrate for High Quality Colon Cleansing Phase 4
Completed NCT01738425 - A Clinical Phase I Study on GIC-1001 in Healthy Volunteers Phase 1
Completed NCT04080843 - Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients Phase 2
Terminated NCT04644315 - A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors Phase 2
Completed NCT02291445 - Comparing a 182mg Colon-targeted-delivery Peppermint Oil Capsule (Tempocol-ColoPulse®) and a 182mg Enteric-coated Peppermint Oil Capsule (Tempocol®), a Pharmacokinetic Study Phase 2
Completed NCT03037385 - Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors Phase 1/Phase 2
Completed NCT03139942 - Optical Polyp Testing for In Vivo Classification N/A
Completed NCT04263818 - Endoscopist and Endoscope Motions During Colonoscopy N/A
Recruiting NCT05923918 - A Study to Evaluate Safety and Efficacy of PBK_M2101 Phase 3
Completed NCT02647866 - Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis Phase 2
Completed NCT01397747 - Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer N/A